Lamont Terrell

US Patent:

20090275581, Nov 5, 2009

Filed:

Apr 5, 2007

Appl. No.:

12/225987

Inventors:

John J. Baldwin - Gwynedd Valley PA, US
David A. Claremon - Maple Glen PA, US
Colin M. Tice - Amber PA, US
Salvacion Cacatian - Blue Bell PA, US
Lawrence W. Dillard - Yardley PA, US
Alexey V. Ishchenko - Somerville MA, US
Jing Yuan - Landsdale PA, US
Zhenrong Xu - Horsham PA, US
Gerard McGeehan - Garnet Valley PA, US
Wei Zhao - Eagleville PA, US
Robert D. Simpson - Wilmington DE, US
Suresh B. Singh - Kendall park NJ, US
Patrick T. Flaherty - Pittsburgh PA, US
Lara S. Kallander - King of Prussia PA, US
Colin A. Leach - King of Prussia PA, US
Brian Lawhorn - King of Prussia PA, US
Qing Lu - King of Prussia PA, US
Lamont R. Terrell - King of Prussia PA, US
Jing Zhang - King of Prussia PA, US
Damiano Ghirlanda - King of Prussia PA, US
Xiaoping Hou - King of Prussia PA, US
Simon Semus - King of Prussia PA, US

International Classification:

A61K 31/5377
C07D 207/14
A61K 31/40
C07D 211/32
A61K 31/445
A61K 31/4545
C07D 401/10
C07D 413/06
A61P 9/12

US Classification:

5142355, 548539, 514423, 546226, 514330, 514316, 546191, 544141

Abstract:

Disclosed are compounds according to Formula I:wherein the variables are defined herein. Such compounds are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity.Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to Formula I.

US Patent:

20100130471, May 27, 2010

Filed:

Apr 4, 2008

Appl. No.:

12/450619

Inventors:

John J. Baldwin - Gwynedd Valley PA, US
Salvacion Cacatian - Blue Bell PA, US
David Claremon - Maple Glen PA, US
Lawrence W. Dillard - Yardley PA, US
Patrick T. Flaherty - Pittsburgh PA, US
Damiamo Ghirlanda - Legnago, IT
Xiaoping Hou - Pennington NJ, US
Lara S. Kallander - King of Prussia PA, US
Beth A. Knapp-Reed - King of Prussia PA, US
Brian Lawhorn - King of Prussia PA, US
Qing Lu - King of Prussia PA, US
Gerard McGeehan - Garnet Valley PA, US
Simon Semus - Collegeville PA, US
Robert D. Simpson - Wilmington DE, US
Suresh B. Singh - Kendall Park NJ, US
Lamont R. Terrell - King of Prussia PA, US
Colin Tice - Ambler PA, US
Tritin Tran - King of Prussia PA, US
Zhenrong Xu - Horsham PA, US
Jing Yuan - Lansdale PA, US
Jing Zhang - Waltham MA, US
Wei Zhao - Eagleville PA, US

International Classification:

A61K 31/445
A61K 31/554
A61K 31/55
A61K 31/551
A61K 31/549
A61K 31/5377
A61K 31/5375
A61K 31/4545
C07D 417/12
C07D 265/30
C07D 401/06
C07D 401/10
C07D 211/34
A61P 25/00
A61P 9/12
A61P 9/10

US Classification:

51421107, 51421207, 514221, 5142235, 5142355, 5142362, 5142375, 514316, 514318, 514330, 544133, 544165, 546189, 546194, 546226

Abstract:

Described are compounds which bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.

US Patent:

20100317697, Dec 16, 2010

Filed:

Jun 20, 2008

Appl. No.:

12/665217

Inventors:

John J. Baldwin - Gwynedd Valley PA, US
Salvacion Cacatian - Blue Bell PA, US
David Claremon - Maple Glen PA, US
Lawrence W. Dillard - Yardley PA, US
Patrick T. Flaherty - Pittsburgh PA, US
Damiano Ghirlanda - Legnago, IT
Alexey V. Ishchenko - Somerville MA, US
Lara S. Kallander - King of Prussia PA, US
Brian Lawhorn - King of Prussia PA, US
Qing Lu - King of Prussia PA, US
Gerard McGeehan - Garnet Valley PA, US
Simon Semus - Collegeville PA, US
Robert D. Simpson - Wilmington DE, US
Suresh B. Singh - Kendall Park NJ, US
Lamont R. Terrell - King of Prussia PA, US
Colin Tice - Ambler PA, US
Tritin Tran - King of Prussia PA, US
Zherong Xu - Horsham PA, US
Jing Yuan - Lansdale PA, US
Wei Zhao - Eagleville PA, US
Yongdong Y. Zhao - King of Prussia PA, US

International Classification:

A61K 31/445
C07D 211/06

US Classification:

514330, 546226

Abstract:

Disclosed are compounds having the formula (I): wherein the R, R, R, X, Y, A, L, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

US Patent:

20080242666, Oct 2, 2008

Filed:

Dec 22, 2005

Appl. No.:

11/722732

Inventors:

Colin Andrew Leach - King of Prussia PA, US
John Liddle - Hertfordshire, GB
Simon Peace - Hertfordshire, GB
Joanne Philp - Hertfordshire, GB
Ian Edward David Smith - Hertfordshire, GB
Lamont Roscoe Terrell - King of Prussia PA, US
Jing Zhang - King of Prussia PA, US

International Classification:

C07D 241/08
A61K 31/496
A61K 31/5377
C07D 413/12
C07D 401/12
A61K 31/495
C07D 403/12
A61K 31/551
A61P 5/00
A61P 43/00

US Classification:

5142358, 544383, 51425502, 544121, 544360, 51425301, 51425211, 544357, 51425312, 514218, 540575

Abstract:

The present invention relates to Compound S of Formula (I).

US Patent:

20210299113, Sep 30, 2021

Filed:

Sep 20, 2017

Appl. No.:

16/334400

Inventors:

- Brentford, Middlesex, GB
Carl A. BROOKS - Collegeville PA, US
Brian Griffin LAWHORN - Collegeville PA, US
Peng LI - Collegeville PA, US
Jay M. MATTHEWS - Collegeville PA, US
John Jeffrey McATEE - Collegeville PA, US
Joseph E. PERO - Collegeville PA, US
Matthew Robert SENDER - Collegeville PA, US
Lamont Roscoe TERRELL - Collegeville PA, US
David J. BEHM - Collegeville PA, US

International Classification:

A61K 31/4439
A61K 45/06
C07D 401/12
C07D 207/48
A61K 31/40
C07D 417/12
A61K 31/427
C07D 403/12
A61K 31/506
C07D 498/10
A61K 31/5386

Abstract:

The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

US Patent:

20200261411, Aug 20, 2020

Filed:

Feb 21, 2020

Appl. No.:

16/796989

Inventors:

- Brentford, GB
Carl A. BROOKS - Collegeville PA, US
Brian Griffin LAWHORN - Collegeville PA, US
Guosen YE - Collegeville PA, US
Linda S. BARTON - Collegeville PA, US
Brian W. BUDZIK - Collegeville PA, US
Jay M. MATTHEWS - Collegeville PA, US
John Jeffrey McATEE - Collegeville PA, US
Jaclyn R. PATTERSON - Collegeville PA, US
Joseph E. PERO - Collegeville PA, US
Robert SANCHEZ - Collegeville PA, US
Matthew Robert SENDER - Collegeville PA, US
Lamont Roscoe TERRELL - Collegeville PA, US
David J. BEHM - Collegeville PA, US
James V. THOMAS - Collegeville PA, US

International Classification:

A61K 31/40
C07F 7/08
C07D 513/04
C07D 491/107
C07D 417/12
C07D 409/12
A61K 45/06
A61K 31/695
A61K 31/5386
A61K 31/506
A61K 31/501
A61K 31/4439
A61K 31/429
A61K 31/427
A61K 31/4245
A61K 31/424
A61K 31/4155
A61K 31/407
A61K 31/4025
A61K 9/48
A61K 9/20
A61K 9/00
C07D 498/10
C07D 207/48
C07D 413/12
C07D 401/12
C07D 403/12

Abstract:

The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

US Patent:

20190216774, Jul 18, 2019

Filed:

Sep 20, 2017

Appl. No.:

16/334391

Inventors:

- Brentford, Middlesex, GB
Carl A. BROOKS - Collegeville PA, US
Brian Griffin LAWHORN - Collegeville PA, US
Guosen YE - Collegeville PA, US
Lisa S. BARTON - Collegeville PA, US
Brian W. BUDZIK - Collegeville PA, US
Jay M. MATTHEWS - Collegeville PA, US
John Jeffrey McATEE - Collegeville PA, US
Jacyln R. PATTERSON - Collegeville PA, US
Joseph E. PERO - Collegeville PA, US
Robert SANCHEZ - Collegeville PA, US
Matthew Robert SENDER - Collegeville PA, US
Lamont Roscoe TERRELL - Collegeville PA, US
David J. BEHM - Collegeville PA, US
James V. THOMAS - Collegeville PA, US

International Classification:

A61K 31/40
A61K 9/00
A61K 45/06
C07D 207/48
C07D 413/12
A61K 31/4245
A61K 31/506
C07D 403/12
C07D 409/12
C07D 417/12
A61K 31/4025
A61K 31/427
A61K 31/4155
A61K 31/429
C07D 513/04
C07D 401/12
A61K 31/4439
A61K 31/501
A61K 31/407
C07D 491/107
C07F 7/08
A61K 31/695
A61K 31/5386
C07D 498/10
A61K 31/424
A61K 9/48
A61K 9/20

Abstract:

The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

US Patent:

20100179109, Jul 15, 2010

Filed:

Apr 4, 2008

Appl. No.:

12/450631

Inventors:

Jonh J. Baldwin - Gwynedd Valley PA, US
Salvacion Cacatian - Blue Bell PA, US
David Claremon - Maple Glen PA, US
Lawrence W. Dillard - Yardley PA, US
Patrick T. Flaherty - Pittsburgh PA, US
Damiano Ghirlanda - Legnago, IT
Alexey V. Ishchenko - Somerville MA, US
Lara S. Kallander - King of Prussia PA, US
Brian Lawhorn - King of Prussia PA, US
Colin A. Leach - Collegeville PA, US
Qing Lu - King of Prussia PA, US
Gerard McGeehan - Garnet Valley PA, US
Jaclyn R. Patterson - King of Prussia PA, US
Robert D. Simpson - Wilmington DE, US
Suresh B. Singh - Kendall Park NJ, US
Patrick Stoy - King of Prussia PA, US
Lamont R. Terrell - King of Prussia PA, US
Colin Tice - Ambler PA, US
Zhenrong Xu - Horsham PA, US
Jing Yuan - Lansdale PA, US
Catherine C. K. Yuan - King of Prussia PA, US
Jing Zhang - Waltham MA, US
Wei Zhao - Eagleville PA, US

International Classification:

A61K 31/675
C07D 211/34
A61K 31/445
C07D 265/30
A61K 31/5375
C07D 413/06
A61K 31/5377
A61K 31/535
A61K 31/517
A61K 31/554
A61K 31/4965
A61K 31/5415
A61K 31/55
A61K 31/551
A61K 31/47
A61K 31/566
A61P 25/28
A61P 33/06
A61P 31/18
A61P 9/12
A61P 9/10
A61P 25/22
A61P 27/06

US Classification:

514 91, 546226, 514330, 544162, 5142375, 544131, 5142355, 5142335, 544146, 51425217, 51421107, 51425506, 5142242, 51421207, 514221, 514307, 51421105, 514171

Abstract:

Disclosed are compounds of Formula (I) wherein the R, R, R, R, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.